AGMB ▲ +0.8% - AgomAb Therapeutics NV $AGMB - Agomab Reports Positive Topline Data from STENOVA Open-Label Extension Study of Ontunisertib in Fibrostenosing Crohn's Disease 01-OCT-2026 06:30 AM ET